- Home
- SHOT vs AKTX Comparison
SHOT vs AKTX Comparison
Compare SHOT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- AKTX
- Stock Information
- Founded
- SHOT 2018
- AKTX N/A
- Country
- SHOT United States
- AKTX United States
- Employees
- SHOT N/A
- AKTX N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- AKTX Health Care
- Exchange
- SHOT Nasdaq
- AKTX Nasdaq
- Market Cap
- SHOT 30.4M
- AKTX 37.2M
- IPO Year
- SHOT 2020
- AKTX N/A
- Fundamental
- Price
- SHOT $0.43
- AKTX $1.14
- Analyst Decision
- SHOT
- AKTX
- Analyst Count
- SHOT 0
- AKTX 0
- Target Price
- SHOT N/A
- AKTX N/A
- AVG Volume (30 Days)
- SHOT 6.3M
- AKTX 26.9K
- Earning Date
- SHOT 08-13-2025
- AKTX 08-18-2025
- Dividend Yield
- SHOT N/A
- AKTX N/A
- EPS Growth
- SHOT N/A
- AKTX N/A
- EPS
- SHOT N/A
- AKTX N/A
- Revenue
- SHOT $573,336.00
- AKTX N/A
- Revenue This Year
- SHOT N/A
- AKTX N/A
- Revenue Next Year
- SHOT N/A
- AKTX N/A
- P/E Ratio
- SHOT N/A
- AKTX N/A
- Revenue Growth
- SHOT 69.32
- AKTX N/A
- 52 Week Low
- SHOT $0.23
- AKTX $0.85
- 52 Week High
- SHOT $1.77
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- SHOT 54.76
- AKTX 43.82
- Support Level
- SHOT $0.35
- AKTX $1.10
- Resistance Level
- SHOT $0.48
- AKTX $1.18
- Average True Range (ATR)
- SHOT 0.06
- AKTX 0.05
- MACD
- SHOT 0.01
- AKTX 0.00
- Stochastic Oscillator
- SHOT 46.94
- AKTX 39.52
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.